Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.43 |
| ▸ | LMNA | P02545 | 6/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | RORC | P51449 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PYGL | P06737 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6566496 | 0.92 | MEN1 (0.46) | MEN1KMT2ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL6564414 | 0.91 | KMT2A (0.45) | MEN1KMT2ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL6564684 | 0.90 | MEN1 (0.41) | MEN1KMT2ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL6566670 | 0.90 | KMT2A (0.47) | MEN1KMT2ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL6564760 | 0.90 | MAPT (0.46) | MEN1KMT2ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL6564654 | 0.90 | MEN1 (0.41) | MEN1KMT2ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL6564665 | 0.87 | KMT2A (0.43) | MEN1KMT2ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL6565314 | 0.86 | MEN1 (0.47) | MEN1KMT2ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL6564691 | 0.86 | MEN1 (0.48) | MEN1KMT2ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL6566827 | 0.85 | RORC (0.45) | MEN1KMT2ALMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1437344-A1 | BENZENE DERIVATIVES,PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | HRH4, HRH2, HRH1 | MEN1 4143/4885KMT2A 3137/4885LMNA 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.